Video Series

Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE, leads a discussion surrouding early intervention in the management of type 2 diabetes.

Panelists see the 5-year period of the Enhancing Oncology Model as reasonable; they would like see some progress toward permanent value-based payment structures.

Addressing cancer patients' lack of housing or food insecurity affects care outcomes, but how can the Center for Medicare and Medicaid Innovation build this into a reward structure?

Key opinion leaders highlight the triple therapy approach from the most recent GOLD guidelines, including ICS, long-acting beta-agonist (LABA), and long-acting muscarinic antagonist (LAMA).

Inhaled corticosteroids (ICSs) are a key incorporation to COPD treatment strategies.

Cutting the amount of Monthly Enhanced Oncology Services payments and limiting qualifying tumor types will curtail revenue to practices. But after the financial results in the Oncology Care Model, that's by design.

Unlike the Oncology Care Model, the Enhancing Oncology Model will focus on 7 common cancer types, which experts say offers advantages and disadvantages for practices.

David Lieberman, MD, PhD, discusses the results of the phase 3 LAVENDER trial of trofinetide and the phase 3 AVATAR trial of blarcamesine and how patients and families can learn about eligible clinical trials for possible participation.

An expert provides an overview of the RSBQ and CGI score measurement tools and other tools/methods of assessment used in clinical practice.

Expert panelists navigate optimal treatment strategies for patients with gastroesophageal cancer.

Key social determinants of health impacting MDD are discussed by expert payer panelists.

Drs Chitre and Weaver explore social and health care disparities more prominently affecting various MDD patient populations.

Expert panelists share strategies and considerations for selecting optimal treatment pathways for patients with lupus nephritis.

Alvin Wells, MD, PhD, provides an overview of the lupus nephritis treatment landscape.

The role of combination therapy is explored for the treatment of COPD.

Social determinants of health (SDoH) can create major barriers for access to care.

An expert discusses the current treatment landscape of Rett syndrome including the goals of treatment and implications for utilization management strategies with the disease.

David Lieberman, MD, PhD, reviews the economic burden and long-term complications of Rett syndrome as well as highlights the unmet needs for patients.

James Cleary, MD, PhD, and Laura Bobolts, PharmD, BCOP, highlight new GI and esophageal cancer therapies and their positive impacts on their patient population.

James M. Cleary, MD, PhD, discusses chemotherapy and immunotherapy as appropriate individual strategies, as well as a combination therapy approach for patients with gastroesophageal cancer.

Payers provide insights to health care disparities currently impacting patients with major depressive disorder (MDD).

Jay Weaver, PharmD, MPH, and Mona Chitre, PharmD, CGP, discuss the increased demand for mental health services since the COVID-19 pandemic.

Alvin Wells, MD, PhD, and Jorge Larranaga, MD, highlight the goals of treatment for patients with lupus nephritis.

Key opinion leaders discuss aspects driving care pathways for patients with lupus nephritis.

Social and economic burdens affecting patients with COPD provide significant obstacles to optimizing care.

Jeffrey D. Dunn, PharmD, MBA, leads a panel discussion on disease and treatment landscapes for COPD.

An expert explains how Rett syndrome is diagnosed, how commonly it is misdiagnosed, disease progression, and which providers are best positioned to manage a Rett Syndrome patient.

David Lieberman, MD, PhD, describes Rett syndrome, including the various stages, incidence, and potential causes of this disease.